Form4insider filings, from the source

SEC Form 4 · accession 0001652917-15-000009

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
George Yancopoulos
Officer — President Regeneron Laboratori · Director
Period of report
Dec 2, 2015
Accepted (ET)
Dec 4, 2015 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2Dec 2, 2015S1,098$542.72D542,250D
Common StockF3Dec 2, 2015S602$543.57D541,648D
Common StockF4Dec 2, 2015S4,290$544.52D537,358D
Common StockF5Dec 2, 2015S5,611$545.51D531,747D
Common StockF6Dec 2, 2015S3,038$546.36D528,709D
Common StockF7Dec 2, 2015S914$547.45D527,795D
Common StockF8Dec 2, 2015S3,780$548.49D524,015D
Common StockF9Dec 2, 2015S4,407$549.57D519,608D
Common StockF10Dec 2, 2015S6,390$550.47D513,218D
Common StockF11Dec 2, 2015S4,992$551.43D508,226D
Common StockF12Dec 2, 2015S3,625$552.54D504,601D
Common StockF13Dec 2, 2015S1,600$553.32D503,001D
Common StockF14Dec 2, 2015S1,101$554.58D501,900D
Common StockF15Dec 2, 2015S1,900$555.26D500,000D
Common StockNov 16, 2015G1,612$0.00D567,976Iby Trust
Common Stockholding———5,654IBy 401(k) Plan

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses